Migalastat vs pegunigalsidase alfa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Fabry Disease
Shared mechanism: Alpha-galactosidase A (GLA / α-Gal A) · full Fabry Disease pipeline
Migalastat · Galafold
Marketed by Amicus Therapeutics and partners
NCT00925301 · Phase 3 · completed
Participants were randomized and double-blinded to migalastat or placebo, with 34 and 33 participants assigned respectively. The primary endpoint was a kidney biopsy measure of GL-3 inclusions, a surrogate pathology measure rather than a direct clinical outcome; 13 of 32 migalastat-treated participants versus 9 of 32 placebo-treated participants achieved the target reduction, but the comparison was not statistically significant (p=0.2996).
Next expected readout: December 2026 · NCT04020055 (registry estimate)
Reported efficacy
Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants (missed)
Result source: NCT00925301
pegunigalsidase alfa
Marketed by Chiesi Farmaceutici and partners
NCT03566017 · Phase 3 · completed
This was a genuine open-label extension of studies PB-102-F03, PB-102-F20, and PB-102-F30, with 97 participants and 81 completing the extension, but it was single-arm and unblinded with no comparator. Its primary focus was treatment-related adverse events rather than a randomized clinical efficacy comparison, so the findings provide useful long-term safety and descriptive follow-up evidence but cannot establish comparative treatment benefit. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Treatment-related Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: October 2027 · NCT05710692 (registry estimate)
Reported efficacy
Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) (met)
Result source: NCT02795676
Results for Fabry Disease
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Migalastat's landscape · pegunigalsidase alfa's landscape